Because high HSPA2 expression was associated with negative prognosis in esophageal SCC, non-small cell lung cancer (NSCLC), and liver hepatocellular cancer (HCC) patients (Zhang et al. 2013; Scieglinska et al. 2014; Fu et al. 2014), it seems that this protein could be a clinically relevant cancer biomarker (Table 3). This evidence concerns the gene HSPA2 and cancer.